The Enteritis drugs in development market research report provides comprehensive information on the therapeutics under development for Enteritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Enteritis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Enteritis and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Enteritis by 12 companies/universities/institutes. The top development phase for Enteritis is preclinical with eight drugs in that stage. The Enteritis pipeline has 12 drugs in development by companies and one by universities/ institutes. Some of the companies in the Enteritis pipeline products market are: BioCurity Pharmaceuticals, Acorda Therapeutics and Beijing Scitech-MQ Pharmaceuticals.
The key targets in the Enteritis pipeline products market include Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2), Prostaglandin E Synthase (Microsomal Glutathione S Transferase 1 Like 1 or Microsomal Prostaglandin E Synthase 1 or p53 Induced Gene 12 Protein or PTGES or EC 5.3.99.3), and N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2).
The key mechanisms of action in the Enteritis pipeline product include Nuclear Factor Kappa B (NFKB) Inhibitor with one drug in Preclinical. The Enteritis pipeline products include four routes of administration with the top ROA being Oral and six key molecule types in the Enteritis pipeline products market including Small Molecule, and Synthetic Peptide.
Enteritis overview
Enteritis is an inflammation of the intestines. It could be either infectious and non-infectious caused by bacteria, viral and protozoans. Secondary infections are caused by radiation, excess alcohol, drug toxicity. Mode of infection is air borne, inhalational, contaminated food, water. Etiology includes primarily pathogens and food poisoning too. Symptoms are primarily diarrhea, dehydration, weight loss, abdominal pain. Diagnosis is through physical examination and laboratory examination. Fecal examination to detect the pathogens causing the infection, CT scan of abdomen to evaluate complications associated and CBP, electrolytes to treat dehydration. Rehydration and antibiotics, antidiarrheals are the primary line of treatments then symptomatic therapy to treat fever, abdominal pain.
For a complete picture of Enteritis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
